RE-BVS – Piemonte Repository

Sfoglia per AUTORE
COSCIA M
Collezione AO Cuneo

Items : 5

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. in British journal of haematology / Br J Haematol. 2025 Mar;206(3):924-929. doi: 10.1111/bjh.19976. Epub 2025 Jan 7.

2025
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Vitale C; Coscia M; Bruno B; Rambaldi A; Laurenti L; Krampera M; Gaidano G; Rivela P; Quaresmini G; Quaglia FM; Moia R; Innocenti I; Deodato M; Frustaci AM; Catania G; Boccellato E; Montalbano MC; Perutelli F;

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Fazi P; Vignetti M; Guarini A; Cuneo A; Piciocchi A; De Propris MS; Nanni M; Del Giudice I; Neri A; De Novi LA; Albano F; Vitale C; Visentin A; Pietrasanta D; Mattiello V; Molinari MC; Liberati AM; Giordano A; Patrizi VB; Gottardi D; Galieni P; Deodato M; Arcari A; Musuraca G; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pietrasanta D; Foà R; Chiarenza A; Penna G; Orsucci L; Levato L; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Murru R; Leone M; Baratè C; Olivieri J; Tisi MC; Stefoni V; Malerba L; Ibatici A; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Farina L; Re F; De Paoli L; Foglietta M; Giordano A; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. in Haematologica / Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.

2014
AO Cuneo

Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M;